



ATTORNEY'S DOCKET NO.: 2003080-0054 (SK-893-US)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Danishefsky *et al.* Examiner: Canella, Karen A.
Serial No.: 09/641,742 Art Unit: 1642
Filed : August 18, 2000
For: NOVEL GLYCOCONJUGATES, GLYCOAMINO ACIDS, INTERMEDIATES
THERETO, AND USES THEREOF

Assistant Commissioner for Patents
Washington, D.C. 20231

STATEMENT FILED PURSUANT TO THE DUTY OF
DISCLOSURE UNDER 37 CFR §§1.56, 1.97 AND 1.98

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants request consideration of this Supplemental Information Disclosure Statement.

PART I: Compliance with 37 C.F.R. §1.97

(Select A, B, C or D below)

- A. ☒ This Supplemental Information Disclosure Statement has been filed:
- ☐ within three months of the filing date of the above identified U.S. Patent application other than a continued prosecution application under § 1.53(d);
 - ☐ within three months of the filing date of the entry of the National Stage, as set forth in 37 C.F.R. §1.491, in an International application;
 - ☒ before the mailing date of the first Office Action on the merits in the above-identified application; or
 - ☐ before the mailing of a first Office Action after the filing of a request for continued examination under § 1.114.

No fee or certification is required.

- B. ☐ This Supplemental Information Disclosure Statement has been filed more than three months after the filing date of the present application and after the mailing date of the first Office

RECEIVED
JUL 08 2002
TECH CENTER 1600/2900

Action, but before the mailing date of any of a final action under 37 C.F.R. §1.113, a Notice of Allowance under 37 C.F.R. §1.311, or an action that otherwise closes prosecution in the application, and:

(check 1 or 2 below)

1. ☐ The fee of \$180 as set forth in 37 C.F.R. §1.17(p) is enclosed, OR
2. ☐ The Applicants hereby certify, as specified in 37 C.F.R. §1.97(e), that

(check a or b below)

- a. ☐ each item of information contained in this Supplemental Information Disclosure Statement was first cited in any communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of the Supplemental Information Disclosure Statement; or
- b. ☐ no item of information contained in this Supplemental Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the Supplemental Information Disclosure Statement was known to any individual designated in 37 C.F.R. §1.56(c) more than three months prior to the filing of this Statement.

C. ☐ This Supplemental Information Disclosure Statement has been filed after the mailing date of either a Final action under 37 C.F.R. §1.113 or a Notice of Allowance under 37 C.F.R. §1.311 and on or before payment of the Issue Fee.

1. The Applicants hereby certify, as specified in 37 C.F.R. §1.97(e), that:
 - a. ☐ each item of information contained in this Supplemental Information Disclosure Statement was first cited in any communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of the Supplemental Information Disclosure Statement; or
 - b. ☐ no item of information contained in this Supplemental Information Disclosure Statement was cited in a communication from a foreign patent

office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the Supplemental Information Disclosure Statement was known to any individual designated in 37 C.F.R. §1.56(c) more than three months prior to the filing of this Statement; AND

2. The Petition Fee of \$180 as set forth in 37 C.F.R. §1.17(p) is enclosed.

D. ☐ This Supplemental Information Disclosure Statement does not comply with any of the provisions set forth above, or is being submitted after the payment of the issue fee; however, Applicants respectfully request that the Statement be placed in the above-referenced file.

PART II - 37 CFR § 1.98 Content of Supplemental Information Disclosure Statement:

☒ Applicants hereby make of record in the above-identified application all patents, publications, applications or other information submitted for consideration by the Office listed on the attached form PTO-1449 (modified). The order of presentation of the patents, publications, applications or other information should not be construed as an indication of the importance.

For each patent, publication, or other information listed that is not in the English language, the following is a concise explanation of the relevance of each non-English language reference listed on the attached form PTO-1449 (modified):

Alternatively, if a written English-language translation of a non-English-language document, or portion thereof, is within the possession, or control of, or is readily available to any individual designated in § 1.56(c), a copy of the translation is provided herein as identified.

PART IV: Remarks

A copy of each of the above-identified U.S. and foreign patent(s), publication(s), application(s) or other information submitted is enclosed unless otherwise indicated on the attached form PTO-1449 (modified). It is respectfully requested that:

1. The Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims;

2. The enclosed form PTO-1449 be signed by the Examiner to evidence that the cited information been fully considered by the Patent and Trademark Office during the examination of this application; and

3. The citations for the patent(s), publication(s), application(s), or other information be printed on any patent which issues from this application.


By submitting this Supplemental Information Disclosure Statement, Applicants make no representation that a search has been performed, of the extent of any search performed, or that more material information may not exist.

By submitting this Supplemental Information Disclosure Statement, Applicants make no representation that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).


By submitting this Supplemental Information Disclosure Statement, Applicants make no representation that the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statements by Applicants, the Examiner is urged to form his or her own conclusions regarding the relevance of the cited materials. An early and favorable action is hereby requested.


Respectfully submitted,


Nadège M. Lagneau, Ph.D.
Reg. No. P-51,908

Choate, Hall & Stewart
Exchange Place
53 State Street
Boston, MA 02109
(617) 248-5000
Date: June 27, 2002

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231
on June 27, 2002


Form PTO-1449 (REV. 8-83)		U.S. Department of Commerce Patent and Trademark Office		Atty. Docket: 2003080-0054 (SK-893-US)		In re Application No. 09/641,742	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>				Applicant: Danishefsky <i>et al.</i>		<div style="writing-mode: vertical-rl; transform: rotate(180deg);"> RECEIVED JUL 08 2002 FEDERAL CENTER 1600/2800 </div>	
				Filing Date: August 18, 2000			



U. S. PATENT DOCUMENTS					
Examiner's Initials	U.S. Patent No.	Applicant	Issue Date	Class	Subclass
	5,053,489	Kufe <i>et al.</i>	10/1/91	530	350
	5,625,030	Williams <i>et al.</i>	4/29/97	528	361
	5,798,090	Longnecker <i>et al.</i>	8/25/98	424	279.1
	5,858,994	Kretzschmar <i>et al.</i>	01/12/99	514	62
	5,807,559	Jondal <i>et al.</i>	9/15/98	424	278.1
	5,871,990	Clausen <i>et al.</i>	2/16/99	435	193
	6,013,779	Wong <i>et al.</i>	1/11/00	536	18.6
	6,238,668	Danishefsky <i>et al.</i>	5/29/01	424	184.1

U.S. PATENT APPLICATIONS					
Examiner's Initials	Serial No.	Applicant	Filing Date		
	* 08/457,485	Taylor-Papadimitriou <i>et al.</i>	June 1, 1995		

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Form PTO-1449
(REV. 8-83)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket:
2003080-0054
(SK-893-US)

In re Application No.
09/641,742

**SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT**

(Use several sheets if necessary)



Applicant: Danishefsky *et al.*

Filing Date:
August 18, 2000

Group:
1642

TECH CENTER 1601/2900

JUL 08 2002

RECEIVED

FOREIGN PATENT DOCUMENTS

Examiner's Initials	Document No.	Country	Date	Translation	
				Yes	No
	EP 341252	EP	11/19/97		
	WO 01/14395	PCT	03/01/01		

Examiner's
Initials

**OTHER DOCUMENTS
(Including Author, Title, Date, Pertinent Pages, Etc.)**

Bilodeau M.T., "Total Synthesis of a Human Breast Tumor Associated Antigen", *J. Am. Chem. Soc.*, 117:7840-7841, 1995.

Boehm T. *et al.*, "Development of a Novel Silyl Ether Linker for Solid-Phase Organic Synthesis" *J. Org. Chem.*, 61:6498-6499, 1996.

Danishefsky *et al.* "From the Laboratory to the Clinic: A Retrospective on Fully Synthetic Carbohydrate-Based Anticancer Vaccines" *Angew. Chem. Int. Ed. Engl.*, 39:836-863, 2000.

Lay L. *et al.*, "Oligosaccharides Related to Tumor-Associated Antigens", *Helv. Chim. Acta*, 77:509-514, 1994.

Randolph J.T. *et al.*, "An Interactive Strategy for the Assembly of Complex, Branched Oligosaccharide Domains on a Solid Support: A Concise Synthesis of the Lewis^b Domain in Bioconjugatable Form", *Angew. Chem. Int. Ed. Engl.*, 33(14):1470-1473, 1994.

* Yura *et al.*, "Preparation of oligosaccharide-linked polystyrene and method for immobilization of lectin and base materials for cells", abstract, Jpn. Kokai Tokyo Koho (Japan), 03 December 1996.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

* Cited document is not at present available to the undersigned, or is available in the file of a prior related application relied upon for an earlier filing date under 35 U.S.C. § 120.